These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

75 related articles for article (PubMed ID: 33826784)

  • 41. Vaccination willingness, vaccine hesitancy, and estimated coverage at the first round of COVID-19 vaccination in China: A national cross-sectional study.
    Wang C; Han B; Zhao T; Liu H; Liu B; Chen L; Xie M; Liu J; Zheng H; Zhang S; Wang Y; Huang N; Du J; Liu YQ; Lu QB; Cui F
    Vaccine; 2021 May; 39(21):2833-2842. PubMed ID: 33896661
    [TBL] [Abstract][Full Text] [Related]  

  • 42. BNT162b2 mRNA Covid-19 Vaccine in a Nationwide Mass Vaccination Setting.
    Roest S; Hoek RAS; Manintveld OC
    N Engl J Med; 2021 May; 384(20):1968-1970. PubMed ID: 33882226
    [No Abstract]   [Full Text] [Related]  

  • 43. Placebo control group in COVID-19 vaccine trials: context and timing matters.
    Dal-Ré R
    Eur J Clin Pharmacol; 2022 Mar; 78(3):523-526. PubMed ID: 34837495
    [No Abstract]   [Full Text] [Related]  

  • 44. Immunogenicity and safety of SARS-CoV-2 vaccines in clinical trials.
    Lim HX; Arip M; Yahaya AAA; Jazayeri SD; Poppema S; Poh CL
    Front Biosci (Landmark Ed); 2021 Nov; 26(11):1286-1304. PubMed ID: 34856768
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Clinical Equipoise in COVID-19 Vaccine Candidate Trials.
    Dal-Ré R
    J Clin Pharmacol; 2021 Sep; 61(9):1249-1250. PubMed ID: 33826784
    [No Abstract]   [Full Text] [Related]  

  • 46. Rationale to continue approving placebo-controlled COVID-19 vaccine trials in LMICs.
    Sisa I; Noblecilla E; Orozco F
    Lancet; 2021 Mar; 397(10277):878. PubMed ID: 33617776
    [No Abstract]   [Full Text] [Related]  

  • 47. A randomized, double-blind, placebo-controlled phase III clinical trial to evaluate the efficacy and safety of SARS-CoV-2 vaccine (inactivated, Vero cell): a structured summary of a study protocol for a randomised controlled trial.
    Akova M; Unal S
    Trials; 2021 Apr; 22(1):276. PubMed ID: 33849629
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Uses of equipoise in discussions of the ethics of randomized controlled trials of COVID-19 therapies.
    Nix HP; Weijer C
    BMC Med Ethics; 2021 Oct; 22(1):143. PubMed ID: 34674679
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Evaluating the Long-term Efficacy of Coronavirus Disease 2019 (COVID-19) Vaccines.
    Lin DY; Zeng D; Gilbert PB
    Clin Infect Dis; 2021 Nov; 73(10):1927-1939. PubMed ID: 33693529
    [TBL] [Abstract][Full Text] [Related]  

  • 50. COVID-19 vaccine research and the trouble with clinical equipoise.
    Friesen P; Caplan AL; Miller JE
    Lancet; 2021 Feb; 397(10274):576. PubMed ID: 33539728
    [No Abstract]   [Full Text] [Related]  

  • 51. US FDA erratic approach to placebo-controlled trials after issuing an emergency use authorization for a COVID-19 vaccine.
    Dal-Ré R
    Vaccine; 2021 Feb; 39(8):1180-1182. PubMed ID: 33516602
    [No Abstract]   [Full Text] [Related]  

  • 52. Trial participants' rights after authorisation of COVID-19 vaccines.
    Dal-Ré R; Orenstein W; Caplan AL
    Lancet Respir Med; 2021 Apr; 9(4):e30-e31. PubMed ID: 33476582
    [No Abstract]   [Full Text] [Related]  

  • 53. The Ethics of Continuing Placebo in SARS-CoV-2 Vaccine Trials.
    Rid A; Lipsitch M; Miller FG
    JAMA; 2021 Jan; 325(3):219-220. PubMed ID: 33315080
    [No Abstract]   [Full Text] [Related]  

  • 54. The granting of emergency use designation to COVID-19 candidate vaccines: implications for COVID-19 vaccine trials.
    Singh JA; Upshur REG
    Lancet Infect Dis; 2021 Apr; 21(4):e103-e109. PubMed ID: 33306980
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Placebo-Controlled Trials of Covid-19 Vaccines - Why We Still Need Them.
    ; Krause PR; Fleming TR; Longini IM; Peto R; Beral V; Bhargava B; Cravioto A; Cramer JP; Ellenberg SS; Figueroa JP; Halloran E; Henao-Restrepo AM; Ryan MJ; Levine MM; Nason M; Nohynek HM; Plotkin S; Rees H; Singh JA; Swaminathan S
    N Engl J Med; 2021 Jan; 384(2):e2. PubMed ID: 33264543
    [No Abstract]   [Full Text] [Related]  

  • 56.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 57.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 58.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 59.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 60.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 4.